Cooley: DOJ Data Rule Will Affect Life Sciences Companies
Life sciences companies should assess whether DOJ’s data transfer rule applies to their data-handling activity, attorneys at Cooley said in a post Thursday (see 2504020022).
Sign up for a free preview to unlock the rest of this article
Companies should review whether they collect bulk sensitive data, identify potential covered transactions and understand their data flows and transfers, said Cooley. Attorneys noted there are potential exemptions to the rule for clinical investigations, regulatory approval data and federally funded research.